Bristol Myers Squibb to Unify Research and Development Organization in 2025
Bristol Myers Squibb (BMY) has announced a strategic restructuring of its research and development functions. Starting January 1, the company will consolidate its R&D operations into a single, unified end-to-end organization to streamline processes and integrate various research stages under one entity. The reorganization aims to improve efficiency across the drug development lifecycle. Cristian Massacesi, currently serving as executive vice president, is slated to lead this new integrated structure, marking a significant shift in how the pharmaceutical giant manages its scientific pipeline.
Tickers: $BMY
Topics: leadership change organizational restructuring R&D integration